Mawer Investment Management Ltd. Sells 74,770 Shares of Twist Bioscience Corporation $TWST

Mawer Investment Management Ltd. lowered its position in shares of Twist Bioscience Corporation (NASDAQ:TWST – Free Report) by 75.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,481 shares of the company’s stock after selling 74,770 shares during the period. Mawer Investment Management Ltd.’s holdings in Twist Bioscience were worth $4,731,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Private Advisory Group LLC purchased a new stake in Twist Bioscience during the third quarter valued at approximately $1,533,000. Russell Investments Group Ltd. raised its stake in shares of Twist Bioscience by 190.8% in the third quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock worth $54,863,000 after purchasing an additional 186,294 shares during the last quarter. Pier 88 Investment Partners LLC acquired a new stake in Twist Bioscience during the 3rd quarter valued at approximately $676,000. Lisanti Capital Growth LLC acquired a new position in Twist Bioscience during the third quarter valued at $5,584,000. Finally, Ritholtz Wealth Management purchased a new stake in shares of Twist Bioscience in the third quarter worth about $327,000.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TWST shares. UBS Group began coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target on the stock. Royal Bank Of Canada set a $137.00 target price on Twist Bioscience in a report on Friday. Jefferies Financial Group set a $125.00 price objective on shares of Twist Bioscience in a report on Thursday. Piper Sandler upped their target price on shares of Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, September 21st. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $141.00.

Read Our Latest Research Report on TWST

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 9,514 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the transaction, the insider owned 63,789 shares in the company, valued at approximately $12,048,466.32. This trade represents a 12.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 8,057 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the transaction, the chief financial officer directly owned 100,576 shares in the company, valued at approximately $18,996,794.88. This trade represents a 7.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock worth $80,489,387 in the last 90 days. Company insiders own 3.08% of the company’s stock.

Key Stories Impacting Twist Bioscience

These are some of the TWST stories that stood out recently:

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $111.60 on Monday. The firm’s 50-day simple moving average is $150.23 and its 200-day simple moving average is $93.07. The company has a market cap of $7.00 billion, a price-to-earnings ratio of -53.40 and a beta of 2.25. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.07. Twist Bioscience had a negative return on equity of 27.53% and a negative net margin of 28.34%. The business had revenue of $126.64 million for the quarter, compared to analyst estimates of $123.55 million. The company’s revenue for the quarter was up 26.7% compared to the same quarter last year. As a group, equities research analysts predict that Twist Bioscience Corporation will post -1.52 earnings per share for the current year.

Twist Bioscience Profile

(Free Report)

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

See Also

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST – Free Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.